CDK4/6 inhibitors in breast cancer
Palbociclib, ribociclib and abemaciclib in hormone receptor-positive breast cancer.
Papers per year
Each bar is 12 months; the last one ends 17 Oct 2026. New trials in the same years: 84, 78, 78, 88, 106.
New guidelines and consensus this year
- Pharmacotherapy for older adults with cancer: a digest of the Japanese clinical practice guidelines (second edition)-breast cancerInt J Clin Oncol2026 Oct
- Romanian Consensus Statement for Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer (HR+/HER2- mBC) and Triple-Negative Metastatic Breast Cancer (mTNBC)Curr Oncol2026 Feb 17
- Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Early Breast Cancer 2025Curr Oncol2026 Feb 12
All papers from the last 12 months
934 papers (18 Oct 2025 – 17 Oct 2026), newest first. Loading the full list…
- The peripheral immune landscape of human breast cancerOncoimmunology2026 Dec 31PMID 42393830Review
- Efficacy and safety profiles of CDK4/6 inhibitor in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC) from the high-altitude versus low-altitude regions: a multi-center retrospective studyCancer Biol Ther2026 Dec 31PMID 42337391
- Structure-based drug repurposing for CDK6: Molecular docking and molecular dynamics characterization of FDA-approved non-oncological compoundsJ Mol Graph Model2026 DecPMID 42829998
- Letter to the editor regarding to 'the impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer'Ann Med2026 DecPMID 41729058
- Comment on 'the impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer'Ann Med2026 DecPMID 41693334
- Regarding: "the impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer"Ann Med2026 DecPMID 41620845
- Letter to the editor regarding: 'The impact of body mass index on the efficacy of CDK4/6 inhibitors in patients with metastatic breast cancer'Ann Med2026 DecPMID 41457854
- A PROTAC-inspired bifunctional small molecule recruits CDK6 to target EYA2 degradation and suppress breast tumor growthEur J Med Chem2026 Nov 5PMID 42335715
- Beyond poly(ADP-ribose) polymerase inhibition: emerging therapeutic strategies for germline BRCA1/2 -mutated and PALB2 -mutated breast cancersCurr Opin Oncol2026 Nov 1PMID 42762135Review
- Gedatolisib after CDK4/6 inhibition in HR-Positive/HER2-negative advanced breast cancer: pharmacology, phase iii evidence, and therapeutic positioningExpert Opin Pharmacother2026 Oct 17PMID 42888943Review
More oncology trends
All specialties →Personalised cancer vaccines
mRNA and neoantigen vaccines tailored to a patient's tumour.
AI in cancer pathology
Deep learning on digital pathology slides.
Cell therapy in solid tumours
CAR-T, TIL and TCR-T therapies for solid tumours.
Radioligand therapy
Radioactive drugs that target tumour receptors, such as lutetium-177 PSMA.
Key point: Most international guidelines endorse 177Lu-PSMA-617 for PSMA-positive metastatic castration-resistant prostate cancer after prior ARPI and taxane chemotherapy.
KRAS inhibitors
Drugs targeting KRAS mutations, such as sotorasib and adagrasib.
Multi-cancer early detection
Blood tests that screen for many cancers at once.
Too many papers to read?
PubDaily picks the ones that matter in your specialty and summarises them, about 10 minutes a week.
How these numbers are counted
PubMed query, searched in titles and abstracts by publication date:
(CDK4/6[tiab] OR palbociclib[tiab] OR ribociclib[tiab] OR abemaciclib[tiab]) AND breast[tiab]Trials: ClinicalTrials.gov studies first submitted in each 12-month window that match the same terms. A query can miss synonyms or catch unrelated papers, so treat counts as approximate.